Specifically targeting ERK1 or ERK2 kills Melanoma cells by Qin, Jianzhong et al.
RESEARCH Open Access
Specifically targeting ERK1 or ERK2 kills
Melanoma cells
Jianzhong Qin
1, Hong Xin
2 and Brian J Nickoloff
3,4*
Abstract
Background: Overcoming the notorious apoptotic resistance of melanoma cells remains a therapeutic challenge
given dismal survival of patients with metastatic melanoma. However, recent clinical trials using a BRAF inhibitor
revealed encouraging results for patients with advanced BRAF mutant bearing melanoma, but drug resistance
accompanied by recovery of phospho-ERK (pERK) activity present challenges for this approach. While ERK1 and
ERK2 are similar in amino acid composition and are frequently not distinguished in clinical reports, the possibility
they regulate distinct biological functions in melanoma is largely unexplored.
Methods: Rather than indirectly inhibiting pERK by targeting upstream kinases such as BRAF or MEK, we directly
(and near completely) reduced ERK1 and ERK2 using short hairpin RNAs (shRNAs) to achieve sustained inhibition of
pERK1 and/or pERK2.
Results and discussion: Using A375 melanoma cells containing activating BRAF
V600E mutation, silencing ERK1 or
ERK2 revealed some differences in their biological roles, but also shared roles by reduced cell proliferation, colony
formation in soft agar and induced apoptosis. By contrast, chemical mediated inhibition of mutant BRAF (PLX4032)
or MEK (PD0325901) triggered less killing of melanoma cells, although they did inhibit proliferation. Death of
melanoma cells by silencing ERK1 and/or ERK2 was caspase dependent and accompanied by increased levels of
Bak, Bad and Bim, with reduction in p-Bad and detection of activated Bax levels and loss of mitochondrial
membrane permeability. Rare treatment resistant clones accompanied silencing of either ERK1 and/or ERK2.
Unexpectedly, directly targeting ERK levels also led to reduction in upstream levels of BRAF, CRAF and pMEK,
thereby reinforcing the importance of silencing ERK as regards killing and bypassing drug resistance.
Conclusions: Selectively knocking down ERK1 and/or ERK2 killed A375 melanoma cells and also increased the
ability of PLX4032 to kill A375 cells. Thus, a new therapeutic window is open for future clinical trials in which
agents targeting ERK1 and ERK2 should be considered in patients with melanoma.
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Background
The incidence of melanoma is on the rise [1], as is the
number of individuals dying from metastatic melanoma
[2]. There are numerous genetically defined activating
mutations in melanoma cells leading to enhanced activ-
ity of the RAF/MEK/ERK signaling cascade [3-7].
Numerous recent reports focusing on BRAF-targeted
therapy designed to interrupt the RAF/MEK/ERK mito-
gen activated protein kinase (MAPK) pathway in
melanoma patients have not made any distinctions
between ERK1 and ERK2 [8-15]. To our knowledge no
group has attempted to distinguish or target the differ-
ent isoforms of ERK (e.g. ERK1 or ERK2) specifically in
melanoma cells (reviewed in [16]).
Over 20 years ago, it was discovered that a prominent
response to addition of extracellular mitogen to fibro-
blasts triggered a series of intracellular biochemical
events including several kinases such as MEK and
p44
MAPK/ERK1 [17-20] and p42
MAPK/ERK2 [20]. While
ERK1 and ERK2 share 84% amino acid sequence homol-
ogy, knocking out ERK1 vs. ERK2 in mice produces dif-
ferent phenotypes supporting distinct functions for
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provided the original work is properly cited.these isoforms [21,22]. Many components of RAF/MEK/
ERK signaling cascades are mutated or aberrantly
expressed in human cancer cells responsible for trans-
formation accompanied by altered proliferation, survival
and resistance to treatment [23]. As clinicians have refo-
cused their therapeutic strategies including targeting
mutated BRAF, and downstream molecules such as
MEK, the potential efficacy of targeting ERK1 and/or
ERK2 has not been tested [24].
To fill the experimental and therapeutic void regard-
ing the roles for ERK1 and/or ERK2 in human mela-
noma, a cell line containing mutated BRAF (e.g. A375
cells) was studied in detail using shRNAs selective for
each isoform. After confirming effective and selective
silencing of ERK1 and ERK2, a series of experiments
was conducted to evaluate these kinases in melanoma.
While functional differences between ERK1 and ERK2
are controversial depending on the cell type examined
[25], we observed both similar as well as distinct effects
such as differentially involving specific pro-apoptotic
proteins (i.e. Noxa) in A375 cells upon silencing of
ERK1 and ERK2. Given that activation of the ERK path-
way is important in melanoma progression [26], these
findings lay the groundwork for new approaches in
metastatic melanoma using a molecularly-based targeted
approach [27].
Such novel approaches are urgently needed as it is
clear that melanoma cells possess multiple mechanisms
to bypass, or overcome drug resistance to agents with
clinical success such as PLX4032 (Vemurafenib), a drug
targeting mutant BRAF [9,28]. An interesting and rele-
vant common intersection point for the various roads to
PLX4032 resistance is ERK signaling (ibid). Thus, we
decided to expand our studies to not only include silen-
cing of ERK1 and/or ERK2, but to compare and contrast
the biological responses and bypass mechanisms trig-
gered by exposing A375 melanoma cells to PLX4032, as
well as a MEK inhibitor (PD0325901). The results
clearly demonstrate that not only is a combination of
ERK1 and ERK2 superior in triggering a caspase-depen-
dent mode of killing A375 melanoma cells compared to
PLX4032 or PD0325901, but drug resistant clones infre-
quently appear by directly targeting ERK. The ability of
using ERK shRNAs to not only kill melanoma cells, but
to block emergence of treatment resistant clones likely
involves not only reductions in levels of phospho-ERKs,
but also in upstream reductions in BRAF, CRAF and
phospho-MEK thereby interrupting a feedback loop cri-
tical to melanoma survival. ERK shRNAs were also
shown to increase the sensitivity of melanoma cells to
killing by PLX4032 paving the way for combination
therapeutic approaches in melanoma. These results
demonstrate that targeting ERK in melanoma can
overcome the apoptotic resistance of this highly aggres-
sive and difficult to cure tumor.
Methods
Cell culture and chemicals
The human melanoma cell line A375 was purchased
from American Type Culture Collection (Manassas, VA,
USA) and maintained in DMEM (Lonza, Walkersville,
MD, USA) plus 10% FCS (Gemini Bio-Products, Wood-
land, CA) in a humidified incubator (37°C, 5% CO2).
Annexin-FITC was purchased from Biovision Research
Products (Mountain View, CA, USA), and tetra methyl
rhodamine ethyl ester (TMRE) was purchased from
Invitrogen Molecular Probes (Eugene, OR, USA). Pan-
caspase inhibitor ZVAD was purchased from BD Bios-
ciences (San Jose, CA, USA). Propidium iodide (PI) was
p u r c h a s e df r o mS i g m aC h e m i c a lC o( S tL o u i s ,M O ,
USA). PD0325901 and PLX4032 were purchased from
Biovision Research Products (Mountain View, CA, USA)
and Selleck Chemicals (Houston, TX, USA), respectively.
Abs against ERK1, ERK2, pERK1, pERK2, MEK, pMEK,
p-Bad, Bak, Bim, PUMA were purchased from Cell Sig-
naling Technology (Beverly, MA, USA); whereas Bcl-XL,
Mcl-1, Bad, PARP, caspase 3, Raf-1, Raf-B and GAPDH
were purchased from Santa Cruz (Santa Cruz, CA). Ab
against Bcl-2 was from DAKO (Glostrup, Denmark), ab
against actin from Chemicon Int. (Billerica, MA, USA);
Ab against Bax from Calbiochem (San Diego, CA, USA),
and against XIAP and activated Bax from BD Transduc-
tion Lab (Franklin Lakes, NJ, USA). Primary Abs incu-
bated overnight at 4°C, and secondary Abs were
incubated at room temperature for 1 hr.
Production of lentiviral supernatants
Mission TCR shRNAs targeting human ERK1
(NM_002746) and ERK2 (NM_138957) were purchased
from Sigma Chemical Co. pLKO.1 Scramble control
shRNA plasmid, psPAX2 packaging plasmid and pMD2.
G envelope plasmid were provided by Addgene. To
make lentiviral particles, HEK-293 T cells were plated
into 10 cm plates, 2 × 10
6 cell/plate, with 8 ml of
DMEM plus 10% FBS and no antibiotics. On the next
day, for each plate 3 ug of pLKO.1 shRNA plasmid
together with 2.25 ug of psPAX2 and 0.75 ug of pMD2.
G plasmid were transfected with FuGen 6 reagents
(Roche, New Jersey) according to the manufacture’s
instruction. The transfection reagent was removed by
replacing the medium with fresh DMEM containing FBS
and penicillin/streptomycin on the following day. The
cells were incubated at 37°C, 5% CO2 f o r2 4h rf o r
another 2 days. Supernatants from 24 hr and 48 hr
incubations were harvested and combined followed by
centrifugation to remove cell debris and stored at -80°C.
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A375 melanoma cells were plated onto 6 well plates at 3
×1 0
5 cells/well and incubated at 37°C, 5% CO2 over-
night. Cells were washed 1x with PBS and 1 ml of lenti-
viral supernatants containing shRNA for either ERK1 or
ERK2 or scramble control was added in each well. For
ERK1 and ERK2 double knockdown, both supernatants
(1 ml of each) were added into one well. All viral super-
natants were added with hexadimethrine bromide (Sigma
Chemical Co.), final concentration 8 μg/ml) before use.
After 4-6 hr incubation, supernatants were changed with
fresh medium and cells were incubated for another 1 or
2 days before being split for experiments.
Quantitation of cell viability
Cell death was measured by flow cytometry after stain-
ing cells with Annexin-V-FITC and I mg/ml of PI. To
investigate DNA degradation, one of the hallmarks of
apoptosis, cells were fixed with 70% ethanol and PI
stained in the presence of RNAse (10 μg/ml). The rela-
tive percentage of cells with hypo-diploid DNA content
(sub-G0) was determined by FACS analysis and use of
Excel software.
Colony formation assays
For anchorage independent colony formation assay,
A375 cells were transduced with shRNAs for 2 days and
then suspended in DMEM with 0.5% agarose solution,
and plated onto solidified 1% agarose in 6 well plate at a
density of 2500 cells per well in triplicate. A375 cells
were maintained in culture by feeding with 0.5 ml fresh
DMEM plus 10% FBS medium twice a week, for a total
3 weeks. Two independent assays were carried out and
the number of colonies were counted after staining with
0.1% crystal violet solution at the end of each experi-
ment. For anchorage dependent colony assay, A375 cells
infected with shRNAs for 2 days were seeded into 6 well
plates at a density of 2000 cells per well in triplicate.
The cells were cultured with complete DMEM for
another 9 days and colony number counted after being
stained with 0.1% crystal violet solution.
Mitochondrial membrane potential assay
Assessment of mitochondrial membrane potential was
determined by addition of 100 nM of TMRE dye that
accumulates in mitochondria of living cells [29]. Reduc-
tion in TMRE retention is indicative of loss of mito-
chondrial membrane potential.
Detection of intracellular levels of activated BH3-
multidomain proapoptotic bax protein
A375 cells were fixed with 2.5% paraformaldehyde (10
min, room temperature), washed and incubated with a
primary ab detecting the activated configuration of Bax
(BD Pharmingen Inc, San Diego, CA, USA) in FACS
buffer with 0.3% saponin as previously described [30].
The percentage of melanoma cells with activated Bax
was measured by fluorescence intensity greater than
control ab levels.
Immunoblotting
Western blot analysis was performed as previously
described [31]. Briefly, cells were harvested by scraping
and lysed with M-Per mammalian protein extraction
reagent (Thermo Scientific, Rockville, IL, USA) supple-
mented with protease inhibitor cocktail (Roche Diagnos-
tics GmbH, Germany) and phosphatase inhibitor
cocktail set II, (Calbiochem, Los Angeles, CA, USA) fol-
l o w e db ys h a k i n ga n dc e n t r i f u g a t i o na t4 ° C .S u p e r n a -
tants were collected as whole cell extracts and protein
concentrations were measured using Bradford reagents
(Bio-Rad laboratories, Hercules, CA, USA). 30 ug of
proteins were resolved by SDS- PAGE and transferred
to PVDF membrane followed by 1 hr blocking with buf-
fer supplied by LI-COR Biosciences (Lincoln, NE, USA).
Blots were probed with primary Abs overnight at 4°C,
washed and incubated with corresponding fluorescence-
labeled secondary Ab for 1 hr at room temperature in
dark. Protein levels were visualized with LI-COR Infra-
red Imaging System.
Reverse transcriptase-real time PCR
Total RNA was extracted from A375 cells using Trizol
(Invitrogen Life Technologies, Inc.). One microgram of
RNA was reverse transcribed to cDNA using TaqMan
reverse transcription reagents (Applied Biosystems, Fos-
ter City, CA). The following specific primer pairs were
used: BRAF: 5’-CTC GAG TGA TTG GGA GAT TCC
TGC-3’, (forward), 5’-CTG CTG AGG TGT AGG TGC
TGT CAC-3’ (reverse); 18sRNA: 5’-GGC GCC CCC
TCG ATG CTC TTA G-3’,( f o r w a r d ) ,5 ’-GCT CGG
GCC TGC TTT GAA CAC TCT-3’,( r e v e r s e ) .P C R
reaction was performed by adding 25 μlo f2 XS Y B R
Green Supermix (Bio-Rad Laboratories, Hercules, CA,
USA), 19 μl DEPC treated H2O, 2 μl of each primer, 2
μl of diluted cDNA template. DNA amplification was
completed in ABI prism model 7300 thermal cycler. All
reactions were run in triplicate and two independent
assays were performed. The comparative expression
level was determined by applying the calculation of 2
(Δ
Ct B-raf-ΔCt 18s).
Statistical analysis
All statistical analyses were performed using the
unpaired, two sided Student’s t-test, and results consid-
ered significant when P values were less than 0.05.
Qin et al. Journal of Translational Medicine 2012, 10:15
http://www.translational-medicine.com/content/10/1/15
Page 3 of 12Results
ERK1 and ERK2 shRNA selectively knockdown ERK1 and
ERK2 proteins, respectively in A375 melanoma cells,
accompanied by killing of cells involving apoptosis
In A375 cells, constitutive levels for ERK2 are slightly
greater than ERK1, and the pERK2 is also slightly more
abundant compared to pERK1 (Figure 1A). As there are
currently no chemical inhibitors to selectively block
ERK1 versus ERK2 activity [32], lentiviral preparations
containing specific shRNAs were used targeting ERK1
or ERK2. Addition of ERK1 shRNA significantly reduced
protein levels of ERK1 and pERK1 compared to
scrambled control shRNA treatment, as observed begin-
ning on day 2, with greater reduction on day 4 and near
complete absence on day 6. Interestingly, reduction in
ERK1 levels was accompanied by minimal changes in
t h ep r o t e i nl e v e lo fE R K 2a n dp E R K 2( F i g u r e1 A ,l e f t
side panel). Similarly, addition of ERK2 shRNA signifi-
cantly reduced protein levels of ERK2 and pERK2 com-
pared to scrambled control shRNA treatment with
similar kinetics as observed for ERK1 shRNA, with
minimal changes in Erk1 and pErk1 protein levels by
the ERK2 shRNA. Quantitative analysis of a representa-
tive blot on day 4 is presented in Figure 1A-right side
panel. Thus, despite both ERK1 and ERK2 are MEK
substrates; significant reductions in one isoform did not
trigger increased phosphorylation of the other isoform
in A375 cells.
Treatment with shRNAs silencing ERK1 and/or ERK2
did not trigger detectable killing of A375 cells 2 days
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Figure 1 ERK1 and/or ERK2 shRNA treatment of A375 cells selectively reduces total and phosphorylated levels of respective proteins
at days 2, 4 and 6; accompanied by killing of melanoma cells. A. Western blot showing total and phosphorylated protein levels at indicated
time intervals following exposure to shRNAs as indicated. SC: scrambled control; E1: ERK1; E2: ERK2; E1/2: ERK1 and ERK2. Actin levels confirm
equal loading (left side panel). Data presented is representative of three independent experiments. Right side panel shows the relative density
measurement of day 4 treatment levels for indicated proteins. B. Relative killing percentages on days 2, 4, and 6 following exposures to
indicated shRNAs. Percentage of dead cells as described in Methods section using Annexin-PI and FACS analysis. Histograms represent the means
+/- SEM from four independent experiments. Statistical significance portrayed as follows: *p < 0.002; **p < 0.0001. C. Relative killing percentages
on days 2, 4, and 6 following exposures to indicated shRNAs. Percentage of cells undergoing apoptosis (cells with sub-Go DNA content) as
described in Methods section Histograms represent the means +/- SEM from three independent experiments. Statistical significance portrayed as
follows: *p < 0.03; **p < 0.001.
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data not shown), but progressively increased killing was
observed 4 days (p < 0.0001 for ERK1 and ERK1 plus
ERK2 shRNAs; and p <0 . 0 0 2f o rE R K 2s h R N A )a n d6
days (p <0 . 0 0 2f o rE R K 1s h R N Aa n dp <0 . 0 0 1f o r
ERK2 and ERK1 plus ERK2 shRNAs) after infection
( F i g u r e1 B ) .N o t eb yc o m b i n i n gE R K 1p l u sE R K 2
shRNA infections, no significant additive or synergistic
increased killing was observed. To determine the mode
of cell death cells with sub G0 DNA content were also
analyzed and found to be increased (p <0 . 0 3f o rE R K 1
or ERK2 shRNAs at 4 days), and p < 0.001 for ERK1
plus ERK2 shRNA at 6 days pointing to a role for apop-
tosis in the response to the ERK shRNAs (Figure 1C).
ERK1 and ERK2 shRNA triggers reduction in soft agar
colony formation and lack of drug resistance
Next, the biological effect of a sustained reduction in
pERK1 and/or pERK2 on anchorage independent colony
f o r m a t i o ni ns o f ta g a r( F i g u r e2 A )w a sd e t e r m i n e d( 2 1
days). There was significant reduction in melanoma cell
colony forming potential followed treatment with ERK1
shRNA or ERK2 shRNA; with virtually no colonies
forming following combined ERK1 plus ERK2 shRNAs
(all values p < 0.001) as assessed by counting the num-
ber of clones per 10X magnification light microscopy
(Figure 2A lower panel).
To assess potential of anchorage dependent colony
formation, clones of A375 melanoma cells developing
resistance to ERK1 and/or ERK2 shRNA treatment were
determined by visual inspection and manual counting of
the numbers of clones developing after 9 days (Figure
2B). While numerous and easily visible clones were
apparent when cells were treated with SC shRNA, treat-
ment with the ERK shRNAs did not generate any resis-
tant clones when used in combination, and only rare
clones could be identified with single treatment, being
greater for ERK2 shRNA than ERK1 shRNA as assessed
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Figure 2 ERK1 and/or ERK2 shRNA treatment of A375 cells reduces clonogenic expansion and growth of colonies. A. Colony formation
in soft agar after 21 days using A375 cells exposed to shRNAs (upper panel-phase contrast microscopic appearance after crystal violet staining).
Quantification of clone number per 10x microscopic field for cells exposed to shRNAs for duplicate experiments performed with triplicate wells.
(lower panel; all values using ERK1 and/or ERK2 shRNA compared to SC shRNA, p < 0.001). B. Appearance of A375 cells after exposure (9 days) to
indicated shRNAs revealing crystal violet stained clones readily visible in the SC shRNA treated cultures, but rare to absent in the other wells
(upper panel). Quantitation of clone number per well for A375 cells exposed for 9 days to indicated shRNAs for duplicate experiments
performed with triplicate wells (lower panel; all values using ERK1 and/or ERK2 shRNA compared to SC shRNA, p < 0.001).
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lower panel; all reductions p < 0.001).
Knockdown of ERK1 and/or ERK2 triggers killing of A375
melanoma cells involving a caspase dependent cascade
Western blot analysis revealed silencing either ERK1
and/or ERK2 triggered cleavage (activation) of caspase 8
after 4 days and 6 days, with cleaved caspase 3 detected
after 6 days of treatment (Figure 3A). PARP was cleaved
more prominently by ERK2 shRNA compared to ERK1
shRNA (similar to caspase 8) on day 4, and by day 6
ERK1 and/or ERK2 shRNAs triggered near complete
cleavage of PARP. The role of caspases in killing of
A375 cells was studied using the pan-caspase inhibitor,
ZVAD (Figure 3B); which revealed significant blocking
of day 4 cell death by ERK1 shRNA (p <0 . 0 1 ;p <0 . 0 0 2
for ERK2 shRNA and p < 0.02 for ERK1 plus ERK2
shRNAs).
Killing of A375 cells involves alterations in mitochondrial
function
To assess the integrity of the outer mitochondrial mem-
brane potential before and after 2, 4 and 6 days of treat-
ment, A375 cells were labeled with a TMRE dye (Figure
4A), and reduction in the intensity of staining indicating
altered membrane potential was progressively increased
over the time course for ERK1, ERK2 and ERK1 plus
ERK2 shRNAs in A375 cells. Further analysis using abs
detecting the activated forms for Bax in permeabilized
cells with FACS (Figure 4A-lowest panel set), revealed
all shRNA treatments triggered increased levels of acti-
vated Bax within the melanoma cells.
Profiling protein levels regulating survival and death in
A375 cells
Since cell death is regulated by relative levels of various
pro-apoptotic and anti-apoptotic proteins (Figure 4B),
cell extracts were prepared before and 4 days after var-
ious treatments and western blot analysis included a
panel of anti-apoptotic proteins (Figure 4B upper panel),
and pro-apoptotic proteins (Figure 4B lower panel).
Constitutive levels for proteins associated with cell sur-
vival were detected for Bcl-XL, Mcl-1, Bcl-2, and XIAP
(Figure 4B upper panel). Treatment with ERK1 and/or
ERK2 shRNA did not lower these levels. There was
slight increase in XIAP by knocking down ERK1 but not
ERK2, which did not seem to protect cells from the kill-
ing by targeting ERK2. As regards the pro-apoptotic
protein levels (Figure 4B lower panels), knockdown of
ERK1 and/or ERK2 increased levels of Bak, Bax, Bad,
Bim with variable changes in Noxa and PUMA levels,
accompanied by decreased p-Bad levels in the A375
cells. Both Noxa and PUMA appeared to be dependent
on ERK1, consistent with recent report [33]. Overall,
targeting ERKs appeared to more significantly influence
pro-apoptotic protein levels over pro-survival protein
levels.
PLX4032 and PD0325901 rapidly reduce pERK1 and
pERK2, but pERK1/2 levels are restored following
PLX4032 treatment, with killing beginning on day 2 but
without significant increases after 4 and 6 days of
treatment
Treatment with the MEK inhibitor, PD0325901 reduced
ERK1 levels at 4 hr and 8 hr, but eliminated pERK1 and
pERK2 levels between 2 hr and 48 hr (Figure 5A), with
sustained reduction after 4 days (Figure 5B). Treatment
with mutant BRAF specific inhibitor, PLX4032 slightly
influenced ERK1 and ERK2 levels, but eliminated
pERK1 and pERK2 levels up to 24 hr; but this was not
sustained as both phosphorylated isoforms were detect-
able after 48 hr and 4 days (Figure 5A, B, respectively).
Induction of A375 cell killing was rapid (Figure 5C) as
detected at the 2 day assay point, (approximately 20% of
the cell population; p < 0.01 for both drugs), with slight
increases on day 4 (p <0 . 0 0 1f o rb o t hd r u g s )o rd a y6
(p < 0.001 for PD0325901 compound and p <0 . 0 1f o r
PLX4032).
PD0325901 treatment triggered slight reductions in
Bcl-XL, Mcl-1, Bcl-2 after 4 days of treatment, but not
XIAP; whereas PLX4032 triggered greater reductions all
of these pro-survival protein levels, but not XIAP (Fig-
ure 5D). Pro-apoptotic protein levels were either rela-
tively unchanged or diminished by treatment with these
two drugs, which may reflect the overall relatively mod-
est levels of killing achieved during the six-day period of
treatment with PD032509 or PLX4032.
Silencing ERK1 and/or ERK2 reduces upstream kinase
levels including BRAF, CRAF, and pMEK
To explore the molecular basis for lack of emergence of
treatment resistance clones when using ERK1 and/or
ERK2 shRNAs, relative levels of upstream kinases were
determined 4 days after treatment (Figure 6A-left side
panel). Compared to levels observed using SC shRNA,
the levels of BRAF, CRAF, phospho-MEK, but not total
MEK were significantly reduced by either ERK1 shRNA
or ERK2 shRNA, and for BRAF became even lower with
ERK1 and ERK2 shRNA combined. Given the reports of
treatment resistance of melanoma cells to PLX4032, we
compared and contrasted the same upstream kinase
levels after 4 days of treatment with either PLX4032 or
PD0325901 (Figure 6A-right side panel). Compared to
untreated A375 cells, continuous exposure to
PD0325901 lead to increased levels of BRAF, which was
also modified so as to reduce its electrophoretic motility,
accompanied by near complete loss of CRAF and
increased phospho-MEK and slightly reduced total MEK
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BRAF levels, although both CRAF and phospho-MEK
levels were dramatically reduced. Since BRAF levels
appeared to discriminate between the shRNA treatment
that suppressed resistant clone formation and PLX4032
that promoted resistant clone formation, relative mRNA
levels were determined using RT-PCR (Figure 6B). Com-
pared to untreated cells, PD0325901 increased BRAF
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Figure 3 ERK1 and/or ERK2 shRNA triggers caspase cascade including PARP cleavage, and caspase inhibitor partial block of killing of
A375 cells. A. Western blot analysis of caspase 3, caspase 8 and PARP including both intact (inactive) and cleaved (active) forms in A375 cells
on days 2, 4 and 6 following exposure to shRNAs. GAPDH confirms equivalent loading. B). Addition of pan-caspase inhibitor, ZVAD (20 mM; last
2 days) reduces killing of A375 cells triggered by ERK1 and/or ERK2 shRNA. Histograms represent the means +/- SEM from 3 independent
experiments. Statistical significance portrayed as follows: *p < 0.01, **p < 0.02, ***p < 0.002.
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Page 7 of 12mRNA levels, but none to relatively minor changes in
BRAF mRNA levels were observed for all other treat-
ments (PLX4032, ERK1 and/or ERK2 shRNAs), indicat-
ing changes involving non-transcriptional regulatory
elements.
Combining ERK shRNAs with PLX4032 enhances killing of
melanoma cells
As noted in Figure 5A, treatment of A375 cells with
PLX4032 led to a rebound in pERK levels after 48 hrs,
and to determine if this rebound level of pERK contrib-
uted to melanoma treatment resistance associated with
PLX4032 treatment, we first knocked down pERK levels
with the ERK shRNAs (which generate sustained and
selectively knockdown of each pERK isoform (Figure
1A), and then added PLX4032. Compared to the killing
of A375 cells accomplished by either use of ERK
shRNAs or PLX4032 alone (Figure 7), greater killing
was triggered by PLX4032 in the co-presence of ERK1
shRNA, ERK2 shRNA or ERK1 plus ERK2 shRNA (p <
0.001 for all combinations compared to single treatment
values).
Discussion and conclusions
Despite an impressive array of exciting recent results
highlighting the importance of the RAF/MEK/ERK path-
way in melanoma patients, surprisingly these reports did
not make any distinctions between ERK1 and ERK2. By
contrast, we focused on dissecting important similarities
and differences in the biology and therapeutic targeting
efficacy between ERK1 and ERK2 in A375 melanoma
cells. Taken together, the detailed characterization of
the cellular and molecular events in A375 melanoma
cells following silencing of ERK1 and/or ERK2 revealed
many insights of potential therapeutic significance. First,
it is clear that ERK1 and ERK2 control similar, but not
2 days 
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Figure 4 Decreased mitochondrial outer membrane potential by silencing ERK1 and/or ERK2; accompanied by increased levels of
activated Bax. A. Treatment with ERK1 and/or ERK2 shRNAs at indicated time points increase outer mitochondrial membrane permeability as
assessed by TMRE labeling as described in Methods (upper panel). Increased presence of activated Bax detected in A375 cells treated for 4 days
with ERK1 and/or ERK2 shRNA (lower panel). B. Western blot analysis of selected proteins mediating pro-survival (upper panel) versus pro-
apoptosis (lower panel) in A375 cells exposed for 4 days with either shRNAs. GAPDH levels confirm equivalent protein loading.
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Page 8 of 12identical, signaling events in melanoma cells. For exam-
ple, reducing ERK2, but not ERK1 increased levels of
Noxa; yet combining ERK1 plus ERK2 shRNAs reduced
Noxa below constitutive levels; whereas reducing ERK1
but not ERK2 increased XIAP levels (Figure 4B). Also,
while both isoforms compete for MEK, reduction in one
isoform did not lead to increased phosphorylation of the
other isoform in A375 cells (Figure 1A). Second, target-
ing ERK1 and/or ERK2 trigger greater cell death in
A375 cells compared to chemical inhibitors of mutant
BRAF (PLX4032) or MEK (PD0325901) that possessed
similar rapid reductions in phospho-ERK levels (Figures
1A, B, and 5A, B).
Besides the aforementioned attributes of targeting
ERK1 and/or ERK2, there are several other advantages
to this strategy. First, since drug resistance to PLX4032
is linked to recovery of pERK activity [34], it was thera-
peutically beneficial that sustained and near complete
reduction in both pERK1 and pERK2 can be accom-
plished using the shRNAs to obviate this problem. Sec-
ond, along the same line of inquiry, unlike PLX4032
which is preferentially active in tumor cells bearing the
V600E mutation of BRAF, reducing levels of pERK1
and/or 2 does not depend on the mutation status of the
melanoma cell. Indeed, it has been observed that within
melanoma lesions, there can be both clones containing
0
20 
40 
60 
80 
100 
2 days  4 days  6 days 
untreated
PD0325901 
PLX4032 
%
 
D
e
a
d
 
c
e
l
l
s
 
 
C 
* **  *  **  *  ** 
 0    2   4    8  24  48   0   2    4   8  24  48  hrs  
PD0325901 1μM  PLX4032 5μM 
p-ERK 1  
p-ERK 2  
 Erk 1  
 Erk 2  
GAPDH 
A 
p-MEK 
MEK 
p-ERK1  
 Erk 1  
p-ERK2  
Erk 2  
  PD            -       +      - 
  PLX          -       -       + 
4 days 
GAPDH 
B 
PUMA 
Noxa 
Bim 
p-Bad 
Bak 
Bax 
 Bad 
  GAPDH 
         C   PD  PLX 
XIAP 
C   PD PLX 
Bcl-XL 
Mcl-1 
Bcl-2 
GAPDH 
D  4 days 
Figure 5 PD0325901 or PLX4032 treatment of A375 melanoma cells triggers rapid reduction in pERK1 and pERK2 levels but these
levels are restored after 4 days with PLX4032; accompanied by increased killing, and alterations in protein levels regulating survival
and apoptosis. A. Kinetic changes of selected protein levels by immunoblot analysis altered by treatment with PD0325901 (1 μM) or PLX4032 (5
μM) for 2, 4, 8, 24, 48 hr of drug exposure (left side panel). B. Similar analysis of protein levels treated with PD0325901 or PLX4032 after 4 days of
drug exposure (right side panel). GAPDH levels confirm equal protein loading. C. Relative killing percentages of A375 cells on days 2, 4, and 6
following exposure to PD0325901 (1 μM) or PLX4032 (5 μM). Percentage of dead cells as described in Methods section. Killing at 2 days by either
drug (p < 0.01), after 4 days (p < 0.001) and after 6 days (PD0325901, p < 0.001; PLX4032, p < 0.01) based on 3 independent experiments.
Statistical significance portrayed as follows: *p < 0.01, **p < 0.001. D. Western blot analysis of selected proteins mediating pro-survival (left side
panel) versus pro-apoptosis (right side panel) in A375 cells exposed for 4 days to PD0325901 (1 μM) or PLX4032 (5 μM). GAPDH indicates
equivalent protein loading.
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[ 3 5 ] .T h i r d ,b ys i l e n c i n gE R K1 and/or ERK2, the feed-
back loop between ERK and RAF and MEK is inter-
rupted as clearly observed by comparing treatment of
cells with MEK inhibitor which led to increased phos-
pho-MEK as reported by others [36], in contrast to the
decrease in phospho-MEK after our shRNA approach
(see below for more discussion).
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Figure 6 Silencing ERK1 and/or ERK2 reduces protein levels of upstream kinases after 4 days including BRAF, CRAF, and phospho
MEK; while PD0325901 or PLX4032 exposure variably influences these kinases, with less to no effects of any treatments on BRAF
mRNA levels. A. Western blot of upstream kinases in A375 cells 4 days after treatment with shRNAs (left side panel), or after exposure to
PD0325901 (1 μM) or PLX4032 (5 μM) on right side panel. GAPDH confirms equivalent protein loading. B. BRAF mRNA levels after 4 days of
exposure to PD0325901 orPLX4032 (upper panel); or after treatment with shRNAs (lower panel). Histograms represent the means +/- SD based
on three independent experiments.
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Figure 7 Silencing ERK1 and/or ERK2 increase sensitivity of A375 cells to killing by PLX4032. A. Relative killing percentages of A375 cells
by PLX4032 (5 mM; 4 days) alone or when combined with indicated shRNAs. A375 cells were infected with shRNAs for a total of 4 days and
PLX4032 added for the last 2 days. Note compared to either PLX4032 alone or the shRNAs alone, when combined there is increased killing (p <
0.001). Histograms represent the means +/- SEM based on 3 independent experiments. Statistical significance portrayed as follows: **p < 0.001.
Qin et al. Journal of Translational Medicine 2012, 10:15
http://www.translational-medicine.com/content/10/1/15
Page 10 of 12Additional evidence for feedback loops, and significant
molecular complexities became apparent by probing for
changes in BRAF and CRAF with these various treat-
ments. It should be noted that phosphorylation events
amongst the components of this pathway can be either
activating or inhibitory [37]. A simple negative feedback
loop has been suggested whereby activated ERK would
phosphorylate and thereby inhibit further MEK activity
[38]. While blocking ERK with the chemical inhibitors
or the ERK shRNAs would therefore be expected to
enhance phospho-MEK levels, this was only observed
using PD0325901 (Figure 6A). Thus, feedback loops are
more complicated as regards ERK and MEK. In another
scenario, downstream from ERK are phosphatases (e.g.
DUSP) that serve as negative feedback components, and
decreased ERK levels could lead to reduced phospha-
tases thereby facilitating accumulation of phospho-MEK
[39].
Perhaps even greater complexity was uncovered
between ERK and more upstream kinases such as BRAF
and CRAF. In this situation, markedly diminished levels
of BRAF and CRAF accompanied using shRNAs, redu-
cing ERK1 and or ERK2 levels. ERK is known to be able
to hyperphosphorylate members of the RAF serine/
threonine kinase family, leading to decreased signaling,
a n di ti sp o s s i b l et h ea l t e r e dp h o s p h o r y l a t i o nt r i g g e r e d
by decreased ERK levels influenced the ability of the
antibody to recognize BRAF or CRAF due to conforma-
tional changes [38]. Support for this posttranscriptional
modification was providedb yt h eR T - P C Rr e s u l t si n
which the shRNAs did not influence relative mRNA
levels for BRAF (Figure 6B). A feedback loop could also
be observed using the MEK inhibitor as regards
increased BRAF levels and decreased electrophoretic
motility possibly due to hyperphosphorylation [40,41].
While undoubtedly complex, elements of the feedback
loops (both positive and negative) will require explora-
tion beyond the scope of this current work, but are
likely contributors to the lack of emergence of treatment
resistant clones using the ERK shRNAs.
Despite the remaining challenges required to more
fully understand the biology of silencing ERK1 and or
ERK2, it is clear that killing of melanoma cells by silen-
cing ERK1 and/or ERK2 is caspase dependent (Figure
3B), provoking altered mitochondrial function (Figure
4A), and highlights a key role for the ERK signaling
pathway in tumor cell survival [42]. The higher level of
cytotoxicity exhibited by the ERK shRNAs and activa-
tion of caspase cascades also are likely to contribute to
the paucity of treatment resistant clones (Figure 2B)
with our novel therapeutic approach. Furthermore the
ability of PLX4032 to kill A375 melanoma cells was
greatly increased when combined with ERK1 and/or
ERK2 shRNAs (Figure 7), suggesting the possibility of
such combination therapies worthy of a additional study.
Based on the current in-vitro findings, it may be
worth moving forward in the clinic with several drug
combinations to prevent drug resistance to PLX4032,
which would include drugs targeting ERK, or with drugs
targeting MEK. While these findings were consistently
observed in the A375 cell line, future studies are indi-
cated to explore other V600E BRAF mutant bearing cell
lines to compare and contrast with the results for A375
cells. In conclusion, targeting the BRAF-MEK-ERK path-
way for melanoma patients is rapidly accelerating in the
clinic [43,44], and further studies using agents that
silence ERK1 and/or ERK2 should be seriously consid-
ered for future lines of inquiry to overcome the notor-
ious apoptotic resistance and treatment bypass
repertoire of melanoma cells either alone or in combina-
tion with PLX4032 [45].
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